Scilex (SCLX) said Wednesday it has concluded its phase 2 meeting with the US Food and Drug Administration regarding its product candidate SP-103, which is intended for treating neck pain with muscle spasms.
The FDA outlined a clear pathway to a new drug application following the completion of phase 3 trials, the company said.
Shares of Scilex were up 1.5% in recent Wednesday trading.
Price: 1.01, Change: +0.02, Percent Change: +1.51
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。